Order results by:
| Issue | Title | |
| Vol 16, No 2 (2023) | Molecular pharmacology of coenzyme Q10 in the context of treatment of hyperlipidemic conditions | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin | ||
| "... Background. Therapy of hyperlipidemia with synthetic statin drugs is characterized by a number ..." | ||
| Vol 16, No 3 (2023) | Possibilities of using coenzyme Q10 for the treatment of diseases associated with mitochondrial dysfunction and chronic inflammation | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, A. N. Gromov | ||
| "... Background. The enzymatic cofactor coenzyme Q10 (CoQ10) is involved in the synthesis of adenosine ..." | ||
| Vol 18, No 1 (2025) | Amelioration of histopathological damage in mice with induced hyperlipidemia by terpenes and phytosterols extracted from Iraqi chickpea | Abstract PDF (Eng) similar documents |
| N. R. Hwerif, A. R. Abu Raghif, E. J. Kadhim | ||
| "... for 28 days to induce hyperlipidemia. In all experimental groups, the body weight was measured weekly ..." | ||
| Vol 15, No 1 (2022) | The analysis of the consumption level of antihypertensive drugs and statins in a retail pharmacy of the Samara Region in 2015–2020 | Abstract similar documents |
| I. K. Petrukhina, P. A. Lebedev, E. P. Gladunova, T. K. Ryazanova, A. A. Garanin, P. R. Blinkova | ||
| "... drugs, their fixed combinations (FC), as well as statins in the retail sector of the pharmaceutical ..." | ||
| Vol 18, No 2 (2025) | Population consumption of antihypertensive and lipid-lowering drugs in the Russian Federation (SPARDEC) | Abstract similar documents |
| Zh. D. Kobalava, I. K. Petrukhina, P. A. Lebedev, P. R. Blinkova, T. K. Ryazanova, E. P. Gladunova, E. V. Paranina | ||
| "... for sartans, 10.0 rubles for β-blockers, 9.0 rubles for statins. The cost of 1 DDD for FDCs is significantly ..." | ||
| Vol 16, No 1 (2023) | Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program | Abstract similar documents |
| T. O. Bessonova, P. A. Mukhortova, R. A. Teryan, A. D. Bagdasarov, N. Z. Musina | ||
| "... not reached lipid targets on statin therapy, by increasing the frequency of use of ezetimibe, alirocumab ..." | ||
| 1 - 6 of 6 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
